Proactive Investors - Run By Investors For Investors

FDA accepts Sesen Bio's plan to ensure flagship drug vicinium’s manufacturing quality; shares jump

Sesen’s Canada facility produced vicinium for its Phase 2 and 3 clinical trials, but FUJIFILM Diosynth Biotechnologies USA will make the drug for commercial use
bladder health
Vicinium treats patients with high-risk, non-muscle invasive bladder cancer

Shares of Sesen Bio (NASDAQ:SESN) jumped by double-digits Tuesday after announcing the Food and Drug Administration has accepted its analytic comparability plan as the company seeks to commercialize its flagship drug vicinium to treat bladder cancer.

The analytic comparability plan is designed to ensure the consistency of vicinium’s manufacturing quality. Sesen’s facility in Winnipeg, Manitoba produced vicinium for its Phase 2 and 3 clinical trials. But FUJIFILM Diosynth Biotechnologies USA will manufacture the drug for commercial use.

Sesen Bio’s stock recently traded up 24% to $2.71 a share on heavier-than-average volume.

READ: Sesen Bio to present Phase 3 data of its bladder cancer drug

Sesen, based in Cambridge, Massachusetts, said in a statement that it met with the FDA on Monday, and no additional clinical studies will be required.

The company said it will meet the FDA again on June 6 to discuss the registration strategy for vicinium, which treats patients with high-risk, non-muscle invasive bladder cancer who have been treated previously with bacillus Calmette-Guérin.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

View full SESN profile View Profile

Related Articles

scientist at petrie dish
May 15 2019
Here we take a closer look at Midatech Pharma PLC (LON:MTPH)
cancerous cells
March 08 2019
A series of trials underway at major cancer research hospitals are evaluating the company's flagship cancer drug Ampligen
skin
April 17 2019
Driving growth was Lojuxta, used to treat a rare and life-threatening disorder that causes abnormally high levels of bad cholesterol. Its sales grew to €13.6mln, up 14.2% year-on-year

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use